Isn`t safety the most important thing ?? Efficacy studies are done all the time, especially in the big pharma arena. It must be known, though, that safety takes precedence over efficacy when an FDA decision is rendered. By the way, Vivus just opened-down 70%-
As an aside, Contrave has 2 chances of winning approval in January:
1) SLIM - less than 2% probability 2) none- that means zero
So, hopefully OREX has more drugs in the pipeline. Perhaps a pill for severe Depression, since most shareholders(me included) will need one after the contrave announcement.